MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--23andMe, Inc., a privately held, early-stage personal genetics company today announced it had closed its Series A Preferred Stock Financing, which included investments from, among others, Genentech, Inc., Google Inc., MDV- Mohr Davidow Ventures and New Enterprise Associates.
Terms of the financing were not disclosed.
“Achieving this significant funding milestone enables us to move forward with our core mission of connecting people with their own genetic information,” said Linda Avey, co-founder of 23andMe. “We are thrilled and honored to have attracted the backing of such a diverse, proven and innovative group of investors.”
23andMe is focused on empowering individuals to access, explore, and better understand their genetic information, making use of recent advances in DNA analysis technologies and proprietary web-based software tools. The company currently plans to launch at the end of the year and will provide more information at that time.
“Our goal is to allow individuals to gain deeper insights into their ancestry, genealogy and inherited traits and, ultimately, the option to work together to advance the overall understanding of the human genome,” said Anne Wojcicki, co-founder.
The company is being advised by a group of renowned experts in the fields of human genetics, genomics, bio-ethics and bioinformatics.
23andMe, Inc. was founded by Ms. Avey and Ms. Wojcicki in 2006 and is located in Mountain View, California. More information is available at www.23andme.com.
Contact: Media: Sard Verbinnen & Co. Paul Kranhold or Matt Benson, 415-618-8750
Source: 23andMe, Inc.
